{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:46:01Z","timestamp":1771339561729,"version":"3.50.1"},"reference-count":33,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Dart Family Foundation","award":["1UL1TR001102"],"award-info":[{"award-number":["1UL1TR001102"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR068447"],"award-info":[{"award-number":["K23AR068447"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24AR067847"],"award-info":[{"award-number":["K24AR067847"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>In the Denosumab and High-Dose Teriparatide Administration (DATA-HD) study, we reported that 15 months of combined high-dose (HD) teriparatide and denosumab increased mean areal bone mineral density (aBMD) at the hip and spine more than combined denosumab and standard-dose (SD) teriparatide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In the current analysis, we compare the individual rates of aBMD response between the treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Single-site, open-label, randomized controlled trial in which postmenopausal women received either teriparatide 20-\u03bcg daily (SD) or 40-\u03bcg daily (HD) given months 0 through 9, overlapped with denosumab 60 mg, given months 3 through 15 (15 months\u2019 total duration). The proportion of participants in the SD and HD groups experiencing total hip, femoral neck, and lumbar spine aBMD gains of &amp;gt;3%, &amp;gt;6%, and &amp;gt;9% were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Postmenopausal women with osteoporosis completing all study visits (n = 60).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measure(s)<\/jats:title>\n                  <jats:p>aBMD (dual x-ray absorptiometry).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At the end of the 15-month treatment period, a higher proportion of women in the HD group had aBMD increases &amp;gt;3% (83% vs. 58%, P = .037) and &amp;gt;6% (45% vs. 19%, P = .034) at the total hip, and &amp;gt;3% at the femoral neck (86% vs. 63%, P = .044). At the lumbar spine, &amp;gt;3% response rates were similar, whereas the &amp;gt;6% and &amp;gt;9% response rates were greater in the HD group (100% vs. 79%, P = .012 and 93% vs. 59%, P = .003, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Compared with the SD regimen, more women treated with the HD regimen achieved clinically meaningful and rapid gains in hip and spine aBMD. These results suggest that this approach may provide unique benefits in the treatment of postmenopausal osteoporosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgz163","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T10:29:50Z","timestamp":1572604190000},"page":"890-897","source":"Crossref","is-referenced-by-count":15,"title":["Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-8469","authenticated-orcid":false,"given":"Sabashini K","family":"Ramchand","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA"},{"name":"Department of Medicine, Endocrine Unit, Austin Hospital, The University of Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie L","family":"David","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy N","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"issue":"10","key":"2021122101513907100_CIT0001","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int."},{"issue":"11","key":"2021122101513907100_CIT0002","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","article-title":"Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis","volume":"21","author":"Chen","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021122101513907100_CIT0003","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2021122101513907100_CIT0004","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122101513907100_CIT0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone."},{"issue":"12","key":"2021122101513907100_CIT0006","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","article-title":"Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years","volume":"26","author":"Ferrari","year":"2015","journal-title":"Osteoporos Int."},{"issue":"1","key":"2021122101513907100_CIT0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122101513907100_CIT0008","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122101513907100_CIT0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"9041","key":"2021122101513907100_CIT0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"issue":"14","key":"2021122101513907100_CIT0011","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"Jama."},{"issue":"7","key":"2021122101513907100_CIT0012","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"issue":"18","key":"2021122101513907100_CIT0013","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"3","key":"2021122101513907100_CIT0014","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol."},{"issue":"8","key":"2021122101513907100_CIT0015","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"9886","key":"2021122101513907100_CIT0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet."},{"issue":"5","key":"2021122101513907100_CIT0017","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122101513907100_CIT0018","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","author":"Tsai","year":"2019","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"7","key":"2021122101513907100_CIT0019","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporos Int."},{"issue":"2","key":"2021122101513907100_CIT0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"Importance of precision in bone density measurements","volume":"4","author":"Bonnick","year":"2001","journal-title":"J Clin Densitom."},{"issue":"7","key":"2021122101513907100_CIT0021","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021122101513907100_CIT0022","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1185\/030079904X16768","article-title":"Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis","volume":"20","author":"Sebba","year":"2004","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"2021122101513907100_CIT0023","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jocd.2016.01.004","article-title":"Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (Denosumab and Teriparatide Administration) study randomized controlled trial","volume":"19","author":"Leder","year":"2016","journal-title":"J Clin Densitom."},{"issue":"6","key":"2021122101513907100_CIT0024","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bone.2006.06.007","article-title":"Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis","volume":"39","author":"Gallagher","year":"2006","journal-title":"Bone."},{"key":"2021122101513907100_CIT0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone."},{"issue":"6","key":"2021122101513907100_CIT0026","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1359\/jbmr.060314","article-title":"Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis","volume":"21","author":"Ma","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021122101513907100_CIT0027","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2021122101513907100_CIT0028","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","article-title":"Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium","volume":"22","author":"Lindsay","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"19","key":"2021122101513907100_CIT0029","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"3","key":"2021122101513907100_CIT0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bone.2007.04.197","article-title":"Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys","volume":"41","author":"Fox","year":"2007","journal-title":"Bone."},{"issue":"1","key":"2021122101513907100_CIT0031","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int."},{"issue":"4","key":"2021122101513907100_CIT0032","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jbmr.1784","article-title":"Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT","volume":"28","author":"Hansen","year":"2013","journal-title":"J Bone Miner Res."},{"key":"2021122101513907100_CIT0033","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bone.2017.03.042","article-title":"Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide","volume":"99","author":"Zebaze","year":"2017","journal-title":"Bone."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz163\/30340056\/dgz163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/890\/41824467\/jcem_105_3_890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/890\/41824467\/jcem_105_3_890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T01:53:06Z","timestamp":1640051586000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/890\/5610890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz163","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,11,1]]}}}